Sionna Therapeutics News and Activities
Presence
Sionna Therapeutics develops medicines for cystic fibrosis. Its product candidates and research services support patients, healthcare providers, and partners seeking new treatment options for the disease.
Sionna Therapeutics products and services overview:
- Drug discovery
- Cystic fibrosis therapies
- Small molecule medicines
- Research services
Revenue: ~$0 million
Employees: 90
Headquarters: Waltham, United States (USA)
Sionna Therapeutics is one of the...
Sionna Therapeutics is a company listed under the stock ticker SION (US).
Acquisition, funding and merger involving Sionna Therapeutics.
- Sionna Therapeutics has filed its IPO. Its stock ticker will be SION. (posted on February 10 2025).
Executives
View the org chart displaying its 24 main executives
Most searched biographies at Sionna Therapeutics
- Mike Cloonan, Director, President and Chief Executive Officer
- Jo Viney, Director
- Laurie Stelzer, Director
Popular executive movements at Sionna Therapeutics
- Caroline Stark Beer has joined the company as Chief Business Officer (posted on September 8 2025).
Create your alert
to follow the executive moves at Sionna Therapeutics.
Biotechnology
Sionna Therapeutics has 2,405 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).
Popular M&A news in Biotechnology
- Laboratoire Servier has announced the acquisition of Edgewise Therapeutics (posted on June 4 2026).
- Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).
- IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).
Popular contacts in Biotechnology
News
Press releases by Sionna Therapeutics
- Sionna Therapeutics Expands Pipeline with Multiple Clinical Stage Cystic Fibrosis Compounds Through a License Agreement with AbbVie - Sionna Therapeutics
- Sionna Therapeutics Announces Initiation of Two Phase 1 Clinical Trials of SION-719 and SION-451, in Development for Cystic Fibrosis - Sionna Therapeutics
- Sionna Therapeutics Announces Appointment of Jennifer Fitzpatrick as General Counsel - Sionna Therapeutics
- Sionna Therapeutics Announces $182 Million Series C Financing to Advance Clinical Development of Novel Small Molecules in Cystic Fibrosis - Sionna Therapeutics
- Sionna Therapeutics Announces Phase 1 Initiation for SION-109 in Cystic Fibrosis – Sionna Therapeutics
- Sionna Therapeutics to Present Updates on Clinical Progress in Cystic Fibrosis at 42nd Annual J.P. Morgan Healthcare Conference – Sionna Therapeutics
- Sionna Therapeutics Presents Preclinical Data at 2023 North American Cystic Fibrosis Conference Demonstrating Series 2 NBD1 Stabilizers Normalize ΔF508-CFTR Function – Sionna Therapeutics
- Sionna Therapeutics to Present at 2023 North American Cystic Fibrosis Conference – Sionna Therapeutics
- Sionna Therapeutics Announces Presentation of Preclinical Data on NBD1 Stabilizers at 46th European Cystic Fibrosis Conference – Sionna Therapeutics
- Sionna Therapeutics Announces Advancement of Cystic Fibrosis Pipeline Programs and Presentation at J.P. Morgan 41st Annual Healthcare Conference – Sionna Therapeutics
- View more press releases Close
Social media about Sionna Therapeutics
- Sionna Therapeutics on Wikipedia, Google News & Yahoo Finance
- Sionna Therapeutics on LinkedIn, X (Twitter) & YouTube
